Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Double-Blind, Randomized, Three-Arm, Parallel-Group, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)

NCT03522012 is registered in ClinicalTrials.gov with Mycenax Biotech Inc. as lead sponsor.

NCT NCT03522012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03522012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Double-Blind, Randomized, Three-Arm, Parallel-Group, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)
Lead sponsor
Mycenax Biotech Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 17, 2017
Completion date
December 20, 2018
Enrollment
190 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics